Prognostic relevance of receptor tyrosine kinase expression in breast cancer: A meta-analysis

- Receptor tyrosine kinases (RTKs) may facilitate tumor progression if activated aberrantly.
- The effects on prognosis of overexpression of other RTKs beyond HER2 is unknown in breast cancer.
- Our results show that overexpression of various RTKs is associated with poor outcomes.
- Worse OS was seen with overexpression of FGFR 2/3 and EGFR.
- We suggests the clinical evaluation of combination of agents against RTKs or relevant oncogenic nodes.

BackgroundReceptor tyrosine kinases (RTKs) may facilitate tumor progression if activated aberrantly. The prognostic impact of human epidermal growth factor receptor 2 (HER2) overexpression and effectiveness of its therapeutic targeting is well established, but the effects on prognosis of overexpression of other RTKs is unknown. Here we evaluate the association of RTK expression and survival in breast cancer.MethodsPubMed was searched to identify studies evaluating the association between expression of RTKs other than HER2 and survival of women with breast cancer. Published data were extracted and computed into odds ratios (OR) for death at 5 years with 95% confidence intervals (CI). Data were pooled in a meta-analysis using the Mantel-Haenszel random-effect model. For studies reporting data for more than one RTK the lowest and highest OR were used for separate analyses.ResultsSixteen studies comprising 11,056 patients were included in the analysis. There was an association between overexpression of RTKs and decreased 5-year OS and this was highly significant when using highest ORs from studies reporting more than one RTK (OR = 2.42; 95% CI = 1.92-3.06, P < 0.001). Similar results were observed for 5-year BCSS. Worse OS was seen with overexpression of fibroblast growth factor receptor 2/3 (FGFR) (OR = 3.81; 95% CI = 1.79-8.11) and epidermal growth factor receptor (EGFR)/HER1 (OR = 2.45; 95% CI = 1.90-3.15).ConclusionOverexpression of various RTKs is associated with poor outcomes. This data suggests the clinical evaluation of combination of agents against RTKs or relevant oncogenic nodes.